Acquired Hemophilia A (FVIII Deficiency)‎ Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII

Abstract EN

Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII).

It has a high mortality due to bleeding complications.

FVIIa-based bypassing agents are the first line of treatment but not always effective.

Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy.

We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products.